The DOI matches its Crossref record.
Hot Topics in Pharmacogenetics of Age-Related Macular Degeneration
Abstract
Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management. Keywords: Age-related macular degeneration (AMD), age-related maculopathy susceptibility 2 (ARMS2), age-related eye disease study (AREDS), complement factor H (CFH), pharmacogenetics, vascular endothelial growth factor (VEGF).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is some evidence of pharmacogenetic influences on various treatment modalities used in AMD patients, including Age-Related Eye Disease Study (AREDS) supplements, photodynamic therapy (PDT), and anti-vascular endothelial growth factor (anti-VEGF) agents.”
From Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians. (2024) · cites this paper as [16]
Citations
Cites
Still being checked.
Cited by
Towards the application of precision medicine in Age-Related Macular Degeneration
Cascella, R., Strafella, C., Caputo, V., Errichiello, V., Zampatti, S., Milano, F., Potenza, S., Mauriello, S., Novelli, G., Ricci, F., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.11.004 · Cited by 76
Nitroxyl: A Novel Strategy to Circumvent Diabetes Associated Impairments in Nitric Oxide Signaling
Velagic, A., Qin, C. X., Woodman, O. L., Horowitz, J. D., Ritchie, R. H., & Kemp‐Harper, B. K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00727 · Cited by 28
Genetics and Age-Related Macular Degeneration: A Practical Review for Clinicians.
Nguyen, J., Brantley, & Schwartz, S. G. (2024) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1601003 · Cited by 12
“Notably, there is evidence of a pharmacogenetic effect on many of these interventions [15,16].”
BackgroundSelf-citationZhang, Y., & Zhao, G. (2020) · Medical Science Monitor · doi:10.12659/msm.921584 · Cited by 4
Metadata
- Authors
- Grzybowski, A., Kovach, J., Brantley, M., & Schwartz, S.
- Affiliations
- University of Warmia and Mazury in Olsztyn (PL)
- University of Miami (US)
- Vanderbilt University (US)
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2017-03-02
- Volume
- 23
- Issue
- 4
- Pages
- 547-550
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2590186815
- Cited by
- 4
- References
- 0
- Citations by year
- 2024: 1 · 2020: 2 · 2017: 1
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Eye Institute (P30EY014801)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- age-related macular degeneration, pharmacogenetics, complement factor H, ARMS2, AREDS, anti-VEGF therapy, dietary supplementation, neovascular AMD, genetic susceptibility loci, treatment response variability
- MeSH terms
- Age Factors, Humans, Macular Degeneration, Pharmacogenetics, Dietary Supplements, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hot Topics in Pharmacogenetics of Age-Related Macular Degeneration. https://app.cochat.ai/papers/10.2174/1381612822666161208114847
- The paper
- Grzybowski, A., Kovach, J., Brantley, M., & Schwartz, S. (2017). Hot Topics in Pharmacogenetics of Age-Related Macular Degeneration. Current Pharmaceutical Design. https://doi.org/10.2174/1381612822666161208114847
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.